T. Rowe Price Investment Management’s Enliven Therapeutics ELVN Stock Holding History

T. Rowe Price Investment Management’s Portfolio ELVN Stock Details ELVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$15.3M	Buy	+300,891	New	+$12.8M	0.01%	572

Other funds holding ELVN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

T. Rowe Price Investment Management's ELVN Position: Q2 2026 in Review

T. Rowe Price Investment Management opened a new position in Enliven Therapeutics (ELVN) in Q2 2026: 300,891 shares worth $15.3M. The stake represents 0.01% of the portfolio and ranks #572 among its holdings.

210 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

T. Rowe Price Investment Management held 300,891 shares of Enliven Therapeutics worth $15.3M as of Q2 2026.
Enliven Therapeutics was a new T. Rowe Price Investment Management position in Q2 2026.
Enliven Therapeutics made up 0.01% of T. Rowe Price Investment Management's portfolio in Q2 2026, its #572 holding.
210 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.